Side-by-side comparison of AI visibility scores, market position, and capabilities
NYSE: COST | $2.6B Rx revenue 2024 (11th largest US pharmacy); 19%+ prescription growth; below-market drug pricing open to non-members in most states; no PBM markup model
Costco Pharmacy operates as a pharmacy benefit integrated directly into Costco's warehouse membership model, offering prescription drug dispensing at significantly below-market prices by leveraging Costco's bulk purchasing power and low-margin retail philosophy. Founded as an extension of Costco Wholesale's membership warehouse business, the pharmacy operates on the principle that drug costs should be transparent and accessible, a differentiated stance in an industry dominated by opaque PBM pricing arrangements. Costco Pharmacy serves both Costco members and, in most states, non-members who can access the pharmacy counter without a warehouse membership.\n\nThe pharmacy operates across 650+ Costco warehouse locations in the United States, Puerto Rico, and internationally, offering a formulary of generic and brand-name prescription drugs at prices that often undercut major chains by 50–80%. Costco does not participate in most prescription drug insurance networks, which keeps overhead low and pricing simple — members pay a known cash price rather than navigating co-pay structures. The pharmacy also offers compounding services, pet medications, and immunizations at select locations, and integrates with Costco's optical and hearing aid departments to serve the full healthcare needs of its membership base.\n\nCostco Pharmacy is consistently ranked among the lowest-cost pharmacy options in independent drug pricing surveys, creating strong loyalty among members managing chronic conditions or high-cost specialty medications. The pharmacy benefits from Costco's 130 million+ cardholders globally, who view low-cost pharmacy access as one of the core value drivers of their membership. As PBM reform and drug pricing transparency become legislative priorities in the US, Costco's no-frills cash-pay model is increasingly viewed as a reference point for what pharmacy pricing could look like without intermediary markup layers.
New York electronic bond trading (NASDAQ: MKTX) $763M FY2024 revenue; Open Trading $2T+ liquidity, 40% US IG bond electronification, portfolio trading growth competing with Tradeweb and Bloomberg.
MarketAxess Holdings Inc. is a New York City-based electronic fixed income trading platform — publicly traded on the NASDAQ (NASDAQ: MKTX) as an S&P 500 Financials component — operating the leading electronic trading marketplace for US investment-grade corporate bonds, US high-yield bonds, emerging market bonds, municipal bonds, and US Treasury securities through approximately 850 employees globally. In fiscal year 2024, MarketAxess reported revenues of $763 million with record trading volumes in US investment-grade bonds and emerging market credit, as the multi-year electronification trend in bond markets continued to shift institutional fixed income trading from voice broker-dealer phone execution to electronic all-to-all trading on MarketAxess's Open Trading marketplace. CEO Chris Concannon (joined 2023, formerly Cboe Global Markets president) leads MarketAxess's strategy of expanding market share beyond the institutional investment-grade core into rate products (US Treasuries, agency securities), high-yield, and portfolio trading as fixed income electronification accelerates — currently approximately 40% of US investment-grade bonds trade electronically versus 15% in 2015. MarketAxess's Open Trading protocol (anonymous all-to-all price discovery between buy-side, sell-side, and market makers) generated over $2 trillion in liquidity provision in 2024, reducing transaction costs versus bilateral dealer quotes by an average of $0.28 per $100 face value.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.